Edition:
India

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

38.05USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$38.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
147,609
52-wk High
$49.55
52-wk Low
$10.65

Chart for

About

MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializi... (more)

Overall

Beta: --
Market Cap(Mil.): $1,434.94
Shares Outstanding(Mil.): 34.96
Dividend: --
Yield (%): --

Financials

BRIEF-MyoKardia Inc reports Q3 loss per share $0.42

* MyoKardia Inc reports third quarter 2017 financial results and operational progress

03 Nov 2017

BRIEF-MyoKardia expects to initiate next trial of MYK-491 in DCM patients by year-end

* MyoKardia Inc - ‍next trial of MYK-491 in DCM patients expected to initiate by year-end​

27 Sep 2017

BRIEF-MyoKardia announces pricing of public offering of common stock

* MyoKardia announces pricing of public offering of common stock

09 Aug 2017

BRIEF-MyoKardia announces proposed public offering of common stock

* Commenced a proposed underwritten public offering of 3.5 million shares of its common stock Source text for Eikon: Further company coverage:

08 Aug 2017

MyoKardia hits life high after encouraging heart drug data

Shares of MyoKardia Inc hit a record high on Monday after the company said its experimental drug for an inherited heart disease met the main goal in a small mid-stage study.

07 Aug 2017

BRIEF-Myokardia reports Q2 loss per share $0.41

* Myokardia reports second quarter 2017 financial results and operational progress

07 Aug 2017

BRIEF-Myokardia files for offering of up to 9.2 shares of common stock by selling stockholders

* Myokardia Inc files for offering of up to 9.2 shares of common stock by the selling stockholders - sec filing

11 Jul 2017

Earnings vs. Estimates